Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

HHSC Issues Guidance for NFs on Obtaining Written Consent for Treating a Resident with Antipsychotic or Neuroleptic Medication (PL 2022-11)

Last updated on

The Texas Health and Human Services Commission (HHSC) has published Consent for Antipsychotic and Neuroleptic Medications (Provider Letter 2022-11) for Nursing Facilities (NFs).

The Provider Letter (PL) explains that, under current rules, a resident receiving antipsychotic or neuroleptic medications must provide written consent. Written consent can also be given by a person authorized by law to consent on the resident’s behalf. Consent for antipsychotic and neuroleptic medications must be documented on HHSC Form 3713.

Read the PL details.